N-Acetyl Selank Amidate
An enhanced version of Selank with improved stability, studied for anxiety reduction and cognitive enhancement.
What is N-Acetyl Selank Amidate?
N-Acetyl Selank Amidate is a modified version of Selank with N-acetyl and C-amide terminal modifications that improve enzymatic stability and nasal absorption. Like standard Selank, it is a synthetic analogue of the naturally occurring immunopeptide tuftsin, with anxiolytic and nootropic properties.
What N-Acetyl Selank Amidate Is Investigated For
N-Acetyl Selank Amidate is a stability-modified analogue of Selank used for the same anxiolytic, nootropic, and stress-resilience purposes — reducing generalized anxiety, improving focus and mental clarity, and supporting mood under load. The evidence base belongs to the parent peptide Selank, which has moderate Russian clinical data for anxiety disorders and a reasonably characterized GABAergic and BDNF-related mechanism; the amidate variant has no published head-to-head pharmacokinetic or efficacy study of its own. Claims of improved potency or longer duration from the acetyl and amide terminal modifications are biochemically plausible for half-life extension but have not been demonstrated in humans, and the variant is not an approved medicine in any jurisdiction — including Russia, where the parent Selank is registered. Superior-to-Selank positioning is theoretical and forum-driven rather than evidence-based.
History & Discovery
N-Acetyl Selank Amidate is a structural variant of Selank designed to resist enzymatic degradation more aggressively than the parent molecule. The modifications — acetylation of the N-terminus and amidation of the C-terminus — block aminopeptidase and carboxypeptidase cleavage at both ends of the heptapeptide, and are a standard strategy in peptide medicinal chemistry for extending half-life. The same modification pattern has been applied to Semax to produce N-acetyl Semax amidate, and the same general rationale applies here. The parent peptide Selank emerged from the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s as a tuftsin-derived anxiolytic. N-Acetyl Selank Amidate, by contrast, does not have a clear regulatory lineage. It is not a registered medicine in Russia, the EU, the US, or any other jurisdiction. Published peer-reviewed clinical data on the specific acetylated and amidated form are essentially absent. It exists as a product category driven by the research-chemical market, where terminal modifications are promoted on the basis of theoretical PK improvements rather than head-to-head human data. The biochemical argument — that terminal capping extends half-life — is plausible and well-supported for peptides generally, but extrapolating that to clinically meaningful anxiolytic superiority in humans requires studies that have not been done.
How It Works
This is a more stable version of Selank that helps reduce anxiety and improve mental clarity. It works by modulating GABA (the brain's calming neurotransmitter) and BDNF (a brain growth factor) without causing sedation or dependence.
Like Selank, the N-acetyl amidate form modulates GABAergic neurotransmission by allosterically enhancing GABA-A receptor sensitivity. It increases BDNF expression in the hippocampus, promoting neuroplasticity. It also modulates serotonin metabolism and enkephalin levels. The terminal modifications reduce aminopeptidase and carboxypeptidase degradation, increasing the effective dose reaching target receptors. Additional immunomodulatory effects through IL-6 and interferon-gamma modulation.
Evidence Snapshot
Human Clinical Evidence
Limited for the modified form. Standard Selank has moderate clinical data from Russian studies.
Animal / Preclinical
Moderate. Selank anxiolytic and nootropic effects well-demonstrated in animal models.
Mechanistic Rationale
Moderate. GABAergic and BDNF mechanisms are established for Selank.
Research Gaps & Open Questions
What the current literature has not yet settled about N-Acetyl Selank Amidate:
- 01Human PK comparison between standard Selank and N-Acetyl Selank Amidate — the core marketing claim of extended half-life has not been demonstrated in published human data.
- 02Any controlled clinical trial of the specific variant — efficacy and safety data are extrapolated from the Selank parent literature rather than measured directly.
- 03Long-term safety — not studied in any timeframe for this specific variant.
- 04Product-quality studies — independent verification of commercial research-chemical products' identity, purity, and correct terminal modifications is essentially absent.
- 05Comparative efficacy vs. standard Selank for anxiolytic outcomes — claims of superior effect are anecdotal.
- 06Mechanistic confirmation that the acetyl/amide modifications do not alter the peptide's receptor and signaling profile — generally assumed but not rigorously demonstrated for this sequence.
Forms & Administration
Intranasal spray (preferred) or SC injection. Typical dose: 200-600mcg intranasally, 1-3 times daily. Often used in cycles of 2-4 weeks. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Forum-described protocols typically use 200–600 mcg per dose intranasally, often targeting the lower end of the equivalent Selank range on the assumption that the stabilized form produces comparable exposure with a smaller dose. Some users describe 100–400 mcg per dose. There are no approved clinical protocols for this specific variant, and no published human PK data supports specific dose equivalency to standard Selank.
Frequency
Intranasal dosing is typically 1–2 times daily, with some protocols using three daily doses during high-stress periods. The theoretical rationale for the acetyl/amide modifications — longer half-life — would support less frequent dosing than standard Selank, but comparative human PK data to confirm this is absent.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Forum users typically describe 2–4 week cycles, sometimes with breaks to reset. Longer continuous use is not studied. No approved clinical course length exists because no regulatory approval exists.
Protocol Notes
Intranasal delivery is the route described in virtually all user protocols, matching the design rationale inherited from Selank. The acetyl and amide terminal modifications are intended to reduce nasal and systemic peptidase cleavage and thereby deliver more intact peptide to CNS targets. Whether this translates into meaningfully different clinical effect sizes has not been established in humans. Practical administration follows the same pattern as Selank — drops or spray into each nostril, head slightly tilted back, gentle distribution across the nasal mucosa. Nasal irritation is the most common reported side effect. Sourcing is the central practical issue. This variant exists almost entirely in the research-chemical supply chain. Purity, actual peptide content, and correct terminal modification are not independently verified in typical consumer-facing product. The stability advantage is theoretical if the product is not what the label says it is.
N-Acetyl Selank Amidate is not approved as a medicine in any jurisdiction, including Russia. It is not FDA-approved in the United States. It is sold primarily through research-chemical channels not authorized for human use. Use without clinician oversight and verified sourcing is not consistent with any approved clinical framework.
Timeline of Effects
Onset
Anecdotally described as similar to standard Selank — 15–45 minutes to subjective onset of reduced anxiety, calm, or stress resilience. No controlled trials have characterized onset timing for this specific variant. Self-reports of faster or more pronounced onset versus standard Selank are plausible given the intended stability advantage but are not independently verified.
Peak Effect
Anecdotally described as 1–3 hours post-dose. Users often report that effects sustain for longer than standard Selank, consistent with the theoretical half-life extension from terminal capping, but this is not confirmed in peer-reviewed PK comparisons. Cumulative benefit over days to weeks of repeated dosing is reported consistent with the Selank parent literature.
After Discontinuation
Acute effects fade within hours of the last dose. No documented withdrawal syndrome or rebound effect has been described in forum use, consistent with the Selank parent. Longer-term changes attributable to accumulated BDNF-mediated signaling or downstream gene-expression effects may persist for days to weeks.
Common Questions
Who N-Acetyl Selank Amidate Is NOT For
- •Pregnancy — no safety data for this variant; reproductive toxicology not studied.
- •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
- •Known hypersensitivity to Selank, to this variant, or to components of the intranasal vehicle.
- •Severe nasal mucosal disease, chronic rhinitis, or recent nasal surgery — intranasal delivery may be poorly tolerated.
- •Concurrent benzodiazepines or other strong GABAergic sedatives without clinician oversight — theoretical interaction inherited from Selank's preclinical potentiation of diazepam.
- •Pediatric use — no data in pediatric populations in any formulation.
Drug & Supplement Interactions
No clinical interaction data exists specifically for N-Acetyl Selank Amidate. Theoretical interactions mirror those for the parent Selank: potential potentiation of GABAergic sedatives (benzodiazepines, Z-drugs, barbiturates), unclear interaction with serotonergic agents (SSRIs, SNRIs, MAOIs, triptans), and unknown interactions with other nootropic peptides commonly stacked in forum protocols (Semax, Cerebrolysin). The stabilizing modifications do not, to current knowledge, introduce new interaction mechanisms — the parent peptide's mechanistic profile is preserved; only the half-life is intended to differ. However, if half-life is indeed extended, the window during which interactions could occur is correspondingly longer. Patients on any regular psychiatric medication should disclose use to their prescribing clinician. Because the product is not pharmaceutically regulated, interaction risk also includes unidentified impurities or off-target peptides from low-quality suppliers.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Limited data specific to the modified form
- • May interact with GABAergic medications
What We Don't Know
Safety data specific to the N-acetyl amidate form is limited. Extrapolated from Selank data.
Legal Status
United States
Not FDA-approved for any indication. Not a controlled substance, not a recognized dietary supplement ingredient, not a legal cosmetic ingredient. Sold primarily through research-chemical suppliers (not authorized for human use). No legitimate compounding pharmacy pathway has been established for this specific variant. Legal gray zone: not prohibited but not approved.
International
Not approved as a medicine in Russia, CIS countries, the EU, UK, Australia, Canada, or any jurisdiction identified in public regulatory databases. Unlike the parent Selank, this variant has no registered approved indication anywhere. Availability is via research-chemical channels subject to local rules.
Sports & Competition
Not listed by name on the WADA Prohibited List. Because it is not approved by any governmental health authority for human therapeutic use, it may fall under WADA's S0 catch-all category, which prohibits unapproved substances. Athletes subject to WADA code should assume it is prohibited until clarified with their anti-doping authority.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
N-Acetyl Selank Amidate is an FDA-approved or clinically approved form of Selank.
Reality
It is not approved anywhere. The parent Selank is approved in Russia and CIS countries; this specific variant has no registered approved indication in any jurisdiction. Claims that it is a 'next-generation' approved form are false.
Myth
The acetyl/amide modifications make N-Acetyl Selank Amidate clinically superior to standard Selank.
Reality
The modifications are biochemically plausible for extending half-life but have not been shown to produce superior clinical outcomes in human trials, because those trials do not exist. Superiority claims are theoretical and forum-driven, not evidence-based.
Myth
Because it is stabilized, N-Acetyl Selank Amidate is safer than standard Selank.
Reality
Stability is not safety. A longer-lived peptide can extend both desired and undesired effects. Safety of this specific variant has not been studied; any safety inference is extrapolated from the parent peptide, which itself lacks long-term human safety data.
Myth
Research-chemical sources of N-Acetyl Selank Amidate are equivalent in quality to pharmaceutical Selank.
Reality
Pharmaceutical-grade Selank is manufactured under regulated conditions with identity and purity verification. Research-chemical-channel product has no such guarantee, and independent testing has repeatedly found discrepancies between labeled and actual content for peptides in this market segment.
Published Research
14 studiesSARS-CoV-2 Pandemic Impacts on NASA Ground Operations to Protect ISS Astronauts
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Hyperbaric hyperoxia alters innate immune functional properties during NASA Extreme Environment Mission Operation (NEEMO)
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
Sleep research in space: expression of immediate early genes in forebrain structures of rats during the nasa neurolab mission (STS-90)
Biological Macromolecule Crystallization Database, Version 3.0: new features, data and the NASA archive for protein crystal growth data
EXPERIMENTAL INVESTIGATIONS ON ULTRA-LOW FREQUENCY DISPLACEMENT BALLISTOCARDIOGRAPHY. NASA TT F-269
Characterization of the osteoblast-like cell phenotype under microgravity conditions in the NASA-approved Rotating Wall Vessel bioreactor (RWV)
Physical and biological studies with protons and HZE particles in a NASA supported research center in radiation health
Erythroid cell growth and differentiation in vitro in the simulated microgravity environment of the NASA rotating wall vessel bioreactor
A critical study of the absorption of polypeptides in the far-ultraviolet as a means of extraterrestrial life detection. NASA TM X-1131
Atriopeptin (AP-3) in atria and plasma of rats orbited aboard NASA Spacelab (SL3) for seven days
Delivery of recombinant human growth hormone to rats during exposure to microgravity on NASA Space Shuttle Discovery
Quick Facts
- Class
- Nootropic Peptide
- Tier
- C
- Evidence
- Emerging
- Safety
- Moderate Data
- Updated
- Mar 2026
- Citations
- 14PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.